Mesoblast plunges after US FDA requires new trial

Mesoblast (ASX:MSB) shares have plunged by a third after the US Food and Drug Administration asked the biotech company to … Read More

The post Mesoblast plunges after US FDA requires new trial appeared first on Stockhead.

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *